Successful Treatment of Persistent Symptomatic Coronavirus Disease 19 Infection With Extended-Duration Nirmatrelvir-Ritonavir Among Outpatients With Hematologic Cancer.

Catherine Liu,Leah H Yoke,Pooja Bhattacharyya,Ryan D Cassaday,Guang-Shing Cheng,Zahra Kassamali Escobar,Cristina Ghiuzeli,Denise J McCulloch,Steven A Pergam,Pavitra Roychoudhury,Frank Tverdek,Joshua T Schiffer,Emily S Ford

Open forum infectious diseases（2023）

引用 0|浏览11

暂无评分

摘要

Persistent symptomatic coronavirus disease 2019 (COVID-19) is a distinct clinical entity among patients with hematologic cancer and/or profound immunosuppression. The optimal medical management is unknown. We describe 2 patients who had symptomatic COVID-19 for almost 6 months and were successfully treated in the ambulatory setting with extended courses of nirmatrelvir-ritonavir.

查看译文

关键词

persistent symptomatic coronavirus disease,extended duration nirmatrelvir/ritonavir,infection

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要